Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacterial extracellular vesicles from hypervesiculating Lactiplantibacillus plantarum
- Development stage
- Preclinical
- Lead developer
- University of Maryland College Park
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Bacterial extracellular vesicles from hypervesiculating *Lactiplantibacillus plantarum* are genetically engineered probiotic-derived nanovesicles being developed for the treatment of inflammatory bowel disease (IBD), specifically acute colitis. Developed by researchers at the University of Maryland and spun out into Expora Therapeutics, these bacterial extracellular vesicles (BEVs) are produced by a genetically engineered strain of *L. plantarum* that hypervesiculates via the inducible expression of a peptidoglycan-modifying enzyme, resulting in a 66-fold increase in BEV productivity. In preclinical models, these BEVs demonstrate therapeutic efficacy in attenuating acute dextran sulfate sodium (DSS)-induced colitis by reducing mucosal tissue damage and inflammation, offering a more stable and consistent alternative to live probiotic therapies.
- Other names
- bacterial extracellular vesicles from Lactiplantibacillus plantarumhypervesiculating Lactiplantibacillus plantarum BEVshypervesiculating Lactiplantibacillus plantarum extracellular vesiclesLactiplantibacillus plantarum-derived extracellular vesicles
02
Targets
NOD1 (Nucleotide-binding oligomerization domain-containing protein 1)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)TLR1TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TLR6TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on bacterial extracellular vesicles from hypervesiculating Lactiplantibacillus plantarum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacterial extracellular vesicles from hypervesiculating Lactiplantibacillus plantarum.